Leukemia Patient Requires Treatment Within A Month

Children are every parent’s flesh and blood, and in times of emergencies, they are often willing to put everything down to save them.

The family of an 11-year-old leukemia patient is urgently appealing for medical donations to help provide for his treatment’s down payment at the National University Hospital (NUH).

Without the treatment, the young boy may just have about a month to live, according to doctors.

Source

Diagnosed with leukemia at just 6 years old

Yong Hong, an 11-year-old boy from Malaysia, was diagnosed with acute lymphoblastic leukemia since he was 6 years old.

Source

His medical condition requires him to spend an extended period of time in the hospital and he has never attended school as a result.

Yong Hong’s father also left his job as a car repair technician in Malaysia to take care of him.

Source

Yong Hong requires CART-T cell therapy, which is only available in Singapore, for his condition.

Hence, his family decided to move him over so he can receive the treatment he needs.

Only has a month to live without treatment

Yong Hong is currently on his third relapse from leukemia, and doctors estimate that he only has about a month left to live unless he undergoes CAR-T cell therapy.

Source

The procedure is extremely costly and Yong Hong’s family has allegedly sold everything they owned, including their family home, to raise funds.

Even so, they are still unable to afford the down payment of the therapy treatment.

Urgent appeal for medical funds

The family has thus turned to fundraising platform GIVE.asia in hopes of raising the initial down payment for Yong Hong’s treatment.

At the time of writing, the family has raised about S$142,190 of the targeted amount of S$300,000.

If you’re keen on donating to help save Yong Hong’s life, you can do so via GIVE.asia’s fundraising page here.

We hope Yong Hong will be able to receive the treatment he requires soon, and will make a swift recovery soon after.

Featured image from GIVE.asia on Facebook and Facebook.